tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

NBIX Stock Latest News

Neurocrine board of directors authorizes $500M share repurchase program
The FlyNeurocrine board of directors authorizes $500M share repurchase program
1h ago
NBIX
Promising Market Potential and Therapeutic Advancements Drive Buy Rating for Neurocrine’s Crenessity
PremiumRatings
Promising Market Potential and Therapeutic Advancements Drive Buy Rating for Neurocrine’s Crenessity
2h ago
NBIX
Buy Rating on Neurocrine Due to Stabilization Prospects and Competitive Landscape Opportunities
PremiumRatings
Buy Rating on Neurocrine Due to Stabilization Prospects and Competitive Landscape Opportunities
7d ago
NBIX
Neurocrine Biosciences Faces Market Adoption Challenges with CRENESSITY Launch
PremiumCompany Announcements
Neurocrine Biosciences Faces Market Adoption Challenges with CRENESSITY Launch
9d ago
NBIX
Neurocrine’s Potential Upside: Buy Rating Amid Market Overreaction and Pipeline Prospects
PremiumRatings
Neurocrine’s Potential Upside: Buy Rating Amid Market Overreaction and Pipeline Prospects
10d ago
NBIX
Neurocrine initiated with a Hold at Deutsche Bank
PremiumThe FlyNeurocrine initiated with a Hold at Deutsche Bank
10d ago
NBIX
Neurocrine management to meet with Oppenheimer
Premium
The Fly
Neurocrine management to meet with Oppenheimer
11d ago
NBIX
Neurocrine price target lowered to $163 from $165 at Guggenheim
Premium
The Fly
Neurocrine price target lowered to $163 from $165 at Guggenheim
11d ago
NBIX
Neurocrine Biosciences’ Earnings Call: Record Sales & Strategic Growth
PremiumCompany Announcements
Neurocrine Biosciences’ Earnings Call: Record Sales & Strategic Growth
14d ago
NBIX
Neurocrine price target lowered to $148 from $154 at RBC Capital
PremiumThe Fly
Neurocrine price target lowered to $148 from $154 at RBC Capital
14d ago
NBIX
Neurocrine price target lowered to $147 from $157 at Wedbush
PremiumThe Fly
Neurocrine price target lowered to $147 from $157 at Wedbush
14d ago
NBIX
Hold Rating on Neurocrine Due to Below-Expectations Financial Performance and Conservative Sales Guidance
PremiumRatings
Hold Rating on Neurocrine Due to Below-Expectations Financial Performance and Conservative Sales Guidance
14d ago
NBIX
Neurocrine price target lowered to $185 from $190 at H.C. Wainwright
PremiumThe FlyNeurocrine price target lowered to $185 from $190 at H.C. Wainwright
14d ago
NBIX
Cautious Outlook for Neurocrine Amidst Slowing Ingrezza Growth and Uncertain Pipeline Prospects
Premium
Ratings
Cautious Outlook for Neurocrine Amidst Slowing Ingrezza Growth and Uncertain Pipeline Prospects
14d ago
NBIX
Neurocrine price target lowered to $179 from $184 at BofA
Premium
The Fly
Neurocrine price target lowered to $179 from $184 at BofA
14d ago
NBIX
Neurocrine price target lowered to $163 from $172 at Canaccord
PremiumThe Fly
Neurocrine price target lowered to $163 from $172 at Canaccord
14d ago
NBIX
Neurocrine Biosciences Positioned for Long-term Growth Despite Conservative Outlook
PremiumRatings
Neurocrine Biosciences Positioned for Long-term Growth Despite Conservative Outlook
14d ago
NBIX
Neurocrine’s Conservative 2025 Outlook Prompts Hold Rating Amid Potential Growth Opportunities
PremiumRatings
Neurocrine’s Conservative 2025 Outlook Prompts Hold Rating Amid Potential Growth Opportunities
14d ago
NBIX
Positive Outlook on Neurocrine’s Stock Driven by Ingrezza Growth and Promising Crinecerfont Launch
PremiumRatings
Positive Outlook on Neurocrine’s Stock Driven by Ingrezza Growth and Promising Crinecerfont Launch
14d ago
NBIX
Buy Rating Affirmed for Neurocrine: Growth Potential and Conservative Guidance Bolster Confidence
PremiumRatingsBuy Rating Affirmed for Neurocrine: Growth Potential and Conservative Guidance Bolster Confidence
14d ago
NBIX
Neurocrine Biosciences Reports Strong Growth in 2024
Premium
Company Announcements
Neurocrine Biosciences Reports Strong Growth in 2024
14d ago
NBIX
Confident Buy Rating on Neurocrine Driven by Long-term Growth Potential and Pipeline Advancements
Premium
Ratings
Confident Buy Rating on Neurocrine Driven by Long-term Growth Potential and Pipeline Advancements
14d ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >